

Receipt date: 08/28/2006

10/590897  
10/590897 - GAU: 1633  
IAP9 Rec'd PCT/PTO 28 AUG 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: CARMI 1

In re Application of:	)	Conf. No.:
Nir CARMI et al	)	
	)	
IA No: PCT/IL05/000230	)	Art Unit:
	)	
IA Filed: February 24, 2005	)	Examiner:
	)	
Appln. No.: Not yet assigned	)	Washington, D.C.
	)	
	)	August 28, 2006
For: ENZYMES, CELLS AND METHODS)		
FOR SITES SPECIFIC...	)	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Service Window  
Randolph Building, Mail Stop Amendment  
401 Dulany Street  
Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

[X] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.L./

10/590897

IAP9 Rec'd PCT/PTO 28 AUG 2006

[ ] B. before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114; or

[X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached, except as explained below:

Applicant identifies these documents by attaching hereto copies of the forms PTO-892, PTO-1449, PTO/SB/08a and/or PTO/SB/08b (or their BN form equivalents) from the files of the prior application(s) or a fresh BN/SB/08A and/or BN/SB/08B listing these documents, and request that they be considered and made of record in accordance with 37 CFR §1.98(d). Per 37 CFR §1.98(d), copies of these documents need not be filed in this application.

[X] 3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

[ ] 4. Other information being provided for the examiner's consideration follows:

5. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the

Receipt date: 08/28/2006

In re Appln. No. CARMI 1

10/590897

10590897 - GAU:1633


IAP9 Rec'd PCT/PTO 28 AUG 2006

face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK  
Attorneys for Applicant(s)

By:

  
Sheridan Neimark  
Registration No. 20,520

SN:cac  
624 Ninth Street, N.W., Suite 300  
Washington, D.C. 20001-5303  
Telephone: (202) 628-5197  
Facsimile: (202) 737-3528

Receipt date: 08/28/2006

10/590897

10590897 - GAU: 1633

IAP9 Rec'd PCT/PTO 28 AUG 2006

BN/SB/08A/B

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Not yet assigned
		Filing Date	August 28, 2006
		First Named Inventor	Nir CARMi et al
		Group Art Unit	
		Examiner Name	
Sheet 1	of 2	Attorney Docket Number	CARMi 1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US- 6,465,254			
	AB	US- 6,573,425			
	AC	US- 6,664,108			
	AD	US- 6,326,204			
	AE	US- 6,479,652			
	AF	US- 6,489,145			
	AG	US- 5,932,447			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup>	Number <sup>4</sup> Kind Code <sup>5</sup> (if known)			

Examiner Signature	/Maria Leavitt/	Date Considered	03/07/2011
-----------------------	-----------------	--------------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.L./

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Not yet assigned
		Filing Date	August 28, 2006
		First Named Inventor	Nir CARMI et al
		Group Art Unit	
		Examiner Name	
Sheet 2		Attorney Docket Number	Carmi 1

NON PATENT LITERATURE DOCUMENTS /OTHER INFORMATION			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AH	Albert H. et al. "Site-specific integration of DNA into wild-type and mutant lox sites placed in the plant genome". Plant J. 1995 Apr; 7(4): 649-59	
	AI	Lee G. et al. "Role of nucleotide sequences of loxP spacer region in Cre-mediated recombination". Gene. 1998 Aug 17; 216(1): 55-65	
	AJ	Shaikh A et al. "Chimeras of the Flp and Cre recombinases: test of the mode of cleavage by Flp and Cre". Mol Biol. 2000 Sep 8; 302(1): 27-48	
	AK	Santoro S. et al. "Directed evolution of the site specificity of Cre recombinase". Proc Natl. Acad. Sci USA. 2002 Apr. 2; 99(7): 4185-90. Epub 2002 Mar 19	
	AL	Flowers C. et al. "Inhibition of recombinant human immunodeficiency virus type 1 replication by a site-specific recombinase". J Virol. 1997 Apr; 71(4): 2685-92	
	AM	Gopaul D. et al. "Structure of the Holliday junction intermediate in Cre-loxP site-specific recombination". EMBO J. 1998 Jul 15; 17(14): 4175-87.	
	AN	Bucholz F. et al. "Alteration of Cre recombinase site specificity by substrate-linked protein evolution". Nat Biotechnol. 2001 Nov; 19(11): 1047-52	
	AO	Leslie N. "Site-specific recombination in the replication terminus region of Escherichia coli: functional replacement of dif". EMBO J. 1995 Apr 3; 14(7): 1561-70.	
	AP	Saraf-Levy T. et al. "Site-specific recombination of asymmetric lox sites mediated by a heterotetrameric Cre recombinase complex". Bioorg. & Med. Chem. 2006 May 1; 14(9): 3081-9	

Examiner Signature	/Maria Leavitt/	Date Considered	03/07/2011
--------------------	-----------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.L./